MarketInOut Stock Screener Log In | Sign Up
 

Lakefront Biotherapeutics ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Lakefront Biotherapeutics ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,053.59 mln
Float49.01 mln
Earnings Date11/12/2026

EPS

10.52
Robust

P / E

3.01
Deeply undervalued

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

1.04
Highly suspicious

1-Year Forecast

30.44
Fairly priced

Relative Strength

91 / 100
Top performer

Business Description

Lakefront Biotherapeutics NV is a Belgian biotechnology company, founded in 1999 and headquartered in Mechelen, that develops treatments for cancer and immune system diseases across the United States and Europe. The company has several drugs in clinical testing, including therapies for conditions such as lupus, lymphoma, and multiple myeloma, with some of its most advanced treatments produced directly at the point of patient care. It works in partnership with Gilead Sciences and was previously known as Galapagos NV before changing its name in May 2026.

Key Fundamentals

EPS10.52
P/E3.01
ROE20.10
RPS17.74
ROIC92.58
ROA17.09
Interest Cover309
EBITDA, mln674
EV / EBITDA-0.66
EV / EBIT-0.66
Revenue, mln1,153

Quote Details

Last 31.65
Change 0.25 (0.8%)
Open 31.36
Volume 294,935
Turnover 9,334,693
Average Volume 271,322

Financial Ratios

Pre-Tax Profit Margin58
Leverage Ratio1.04
Current Ratio32.83
Price / Book0.53
Price / Tangible Book0.69
Debt / Equity0.00
Price / Sales1.75

Financial Strength

Altman Z-Score13.45
Piotroski F-Score 6 / 9
Beneish M-Score1.04
Price to Graham Number0.26
1-Year Target Price30.44
Short Ratio10.63
Short % of Float8.28

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 5.85% 90 / 100   
1 Month 4.25% 87 / 100   
2 Months 9.06% 86 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog